Morgan Stanley Upgrades Vertex (VRTX) to Overweight
More News related to VRTX
- Vertex Pharma (VRTX) Announces Exercise of Over Allotment Option by Underwriters; Sees $500.5M in Gross Proceeds
- Vertex Pharmaceuticals Announces Exercise of Option by Underwriters of its Public Offering of Common Stock
- Leerink Swann Maintains an 'Outperform' on Vertex Pharmaceuticals (VRTX); Raises PT After Hosting Investor Meeting
- Vertex Pharma (VRTX) Prices 11.5M Shares at $38.50/Share
- Vertex Pharmaceuticals Announces Pricing of Public Offering of Common Stock
More News related to Upgrades
- Knight (KNX), USA Truck (USAK), Werner (WERN) Higher Amid Avondale Upgrades
- William Blair Upgrades Manpower (MAN) Amid Strong Jobs Report
- Pritchard Capital Upgrades Geokinetics (GOK) to Buy
- Argus Upgrades ADC Telecommunications (ADCT) to Buy
- Oppenheimer Upgrades Akamai Tech (AKAM) to Outperform
Morgan Stanley upgrades Vertex Pharma (Nasdaq: VRTX) from Equalweight to Overweight. The firm set a $50 price target.
Traders seem to be cheering the upgrade in this morning's pre-market session: the stock most recently traded at $37.75, up 2.3% from yesterday's close. The firm's new price target represents potential upside of about 32%.
To see all the analyst calls on shares of Vertex, visit our Analyst Ratings page.
Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.
Related Categories
UpgradesStocks Mentioned
-0.90Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
